Arcutis Biotherapeutics, Inc.

NasdaqGS:ARQT

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Drugstores & Retail Pharmacies

💊 Pharmaceuticals

💻 Telehealth

Location

United States

Market Cap

USD 1.64 B

Share Price

USD 13.74

Avg Daily Volume

2,313,753

Change (1 day)

-4.58%

Change (1 year)

45.86%

Change (YTD)

-1.36%

Arcutis Biotherapeutics, Inc. Operating Income Margin for the Trailing 12 Months (TTM) ending March 31, 2025: -57.00%

Arcutis Biotherapeutics, Inc. Operating Income Margin is -57.00% for the Trailing 12 Months (TTM) ending March 31, 2025, a -69.13% change year over year. Operating Income Ratio is the proportion of a company's operating income to its net sales, measuring the efficiency of its core business operations in generating profits.

Arcutis Biotherapeutics, Inc. Operating Income Margin for the Trailing 12 Months (TTM) ending March 31, 2024 was -184.65%, a -96.21% change year over year.
Arcutis Biotherapeutics, Inc. Operating Income Margin for the Trailing 12 Months (TTM) ending March 31, 2023 was -4,874.97%.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Operating Income Margin	Gross Profit Margin	EBIT Margin	EBITDA Margin

NasdaqGS: ARQT

Arcutis Biotherapeutics, Inc.

CEO	Mr. Todd Franklin Watanabe M.A.
IPO Date	Jan. 31, 2020
Location	United States
Headquarters	3027 Townsgate Road
Employees	342
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Drugstores & Retail Pharmacies 💊 Pharmaceuticals 💻 Telehealth

Description

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.